ClinicalTrials.gg
TerminatedNCT03868566Updated Jan 6, 2023

An Open-Label Study to Assess the Hepatic Protection Effect of SNP-612, in Patients With NAFLD

A Phase 2 interventional study of SNP-612 dose1 and SNP-612 dose2 in NASH - Nonalcoholic Steatohepatitis, sponsored by Sinew Pharma Inc.. Terminated at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-01-06.

Sponsored by Sinew Pharma Inc. · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
recruitment difficulties due to Covid-19

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Aug 2017, registered Mar 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Non-alcoholic Fatty Liver Disease with a site in Taiwan — 12 open to participants now, 16 under way, 7 of them phase 3. Non-alcoholic Fatty Liver Disease · Taiwan.

Enrollment
29th of 41
90 · median 145
Started
2017
with 5 others
Phase 2
15 of 48
1 open now
Registered
13th of 48
by date
Lead sponsor
3 of 48
Sinew Pharma Inc.

Among the 48 studies in Non-alcoholic Fatty Liver Disease with a site in Taiwan, this one is the 29th largest by enrollment of the 41 interventional ones that give a count, is one of 6 that started in 2017, is one of 15 in phase 2, and was the 13th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

12 of the 48 studies in Non-alcoholic Fatty Liver Disease with a site in Taiwan are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Non-alcoholic Fatty Liver Disease with a site in Taiwan, or all of them as a file.
02

Study summary

The primary objective of the study is to compare the changes in ALT to baseline among patients with non-alcoholic fatty liver disease (NAFLD) following the 3-month treatment of 3 different dosing regimens of SNP-612. The secondary objectives will be to compare the changes in other liver function tests, cytokeratin-18 (CK-18) fragment level and adverse event / serious adverse event rates.

Read the detailed description

An open-label study will be conducted in medical centers around Taiwan. The objective of the study is to investigate the efficacy and safety of SNP-612 for the treatment of NAFLD.

Subjects who fulfill all the entry criteria and have written informed consent will be enrolled to the study. Considering a 10% drop-out rate, approximately 72 subjects will be enrolled in order to recruit 64 evaluable subject subjects to complete the enrollment.

Subjects will be administered the study agents oral daily for 3 months or until treatment terminates prematurely. Subjects will return to the study center for clinical evaluation once every 4 weeks throughout the treatment period. Clinical assessment procedures and laboratory tests including ultrasound imaging, hematology with differential, biochemistry, liver function panel, and urinalysis, will be performed at each study visit. The primary endpoint assessment will be the reduction of ALT, at completion of Week 12 compared to baseline. With 64 evaluable patients, there will be an 80% chance of detecting a significant difference at a two sided 0.05 significance level.

Subjects who finish treatment or discontinue prematurely from the study for any reason after receiving one or more doses of study agent will be assessed for safety for 2 (±1) weeks after the last study agent dose or longer in the case of any significant AE or abnormal biochemical or clinical finding.

Each subject will participate in the study for approximately 14 weeks (including the enrollment/baseline visit, 3 routine monthly visits during treatment period, and 1 follow-up visit after 2 weeks of the end of treatment).

It is assumed the study will include a 6 months enrollment period and a further 4 months to complete the follow-up for all enrolled patients.

03

Conditions studied

  • NASH - Nonalcoholic Steatohepatitis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 20 years
  2. Body weight ≥ 54 kg
  3. Diagnosis of non-alcoholic steatohepatitis (NASH) as evidenced by imaging or other diagnostic assessments. Subject should have documented liver fat content ≥ 10.0 % as measured by MRI method prior to study agentagent administration.
  4. Phenotypic diagnosis of NASH based on one or more of the following:

    1. (ALT) levels ≥ 1.5x (ULN) on at least two occasions, seven or more days apart, prior to study agent administration
    2. ALT ≥ ULN on at least two occasions, seven or more days apart, prior to study agent administration AND (BMI) ≥ 25 AND diagnosis of Type 2 DM
  5. Have adequate organ functions as defined by the following examinations prior to the start of study treatment:

    1. Hematology: ≥ 9 g/dL, a count ≥ 100 x 10\^9/L, and a white blood cell count ≥ 3.0 x 10\^9/L
    2. Renal: ≥ 90 mL/min (by Cockcroft-Gault equation), serum uric acid \< 9.0 mg/dL
  6. Able to provide written , and understand and comply with the requirements of the study

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following criteria are not eligible to enter the study:

  1. Decompensated or severe liver disease as evidenced by one or more of the following:

    1. Confirmed cirrhosis or suspicion of cirrhosis
    2. Liver transplant
    3. Liver
    4. Ascites
    5. > , or or AST > 5 x ULN, or Alkaline phosphatase (ALP) > 2x ULN
    6. Acute or chronic hepatitis A, B, C, , or other liver diseases affecting liver function.

    Patients with cysts, hemangiomas, or similar abnormalities, are accepted.

  2. History or presence of alcohol abuse, defined as consumption of more than 210 mL of alcohol per week (the equivalent of 14 glasses of 120-mL wine or 14 cans of 350-mL beer), or other substance abuse within the prior two years
  3. Subjects who are unable to undergo an MRI scan.
  4. Subjects have electronically, magnetically and mechanically activated implanted devices, including but not limited to automatic cardioverter defibrillators, cardiac pacemakers, insulin pumps, metallic splinters in the eye, ferromagnetic haemostatic clips in central nervous systems or vascular vessels.
  5. Significant systemic or major illness other than liver disease, including auto-immune disease, coronary artery disease, cerebrovascular disease, malignant neoplasms, pulmonary disease, renal insufficiency, serious psychiatric disease, and/or other serious disease, that, in the opinion of the Investigator would preclude the subject from participating in and completing the study
  6. Documented history of serious allergic reaction to SNP-612 or any structurally related compounds
  7. Diabetic patients who have not maintained a stable dose of oral medication for hyperglycemia or have had more than 10 percent change in their insulin dose over the past two months
  8. Regular use of agents that are potent against hepatitis or affecting lipid metabolisms, including but not limited to HMGCoA reductase inhibitors (statins), fibrates, silymarin, N-acetylcysteine, or anti-TNF therapies.
  9. Pregnant or lactating
  10. Female of who are not committed to taking reliable during the participation of the study and at least 4 weeks after the end of the study treatment
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    SNP-612 dose1

    dose1 once a day orally for 12 weeks

    Drug: SNP-612 dose1

  • Experimental
    SNP-612 dose2

    dose2 once a day orally for 12 weeks

    Drug: SNP-612 dose2

Interventions

  • DrugSNP-612 dose1

    Subjects will take dose1 once a day orally for 12 weeks

  • DrugSNP-612 dose2

    Subjects will take dose2 once a day orally for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change in serum ALT

    A reduction from baseline (i.e. a negative percent value) indicates an improvement in condition

    Time frame: 12 weeks

Secondary outcomes

  1. Change in serum AST

    A reduction from baseline (i.e. a negative percent value) indicates an improvement in condition

    Time frame: 12 weeks

  2. Change in serum Alk-P

    A reduction from baseline (i.e. a negative percent value) indicates an improvement in condition

    Time frame: 12 weeks

  3. Change in serum γ-GT

    A reduction from baseline (i.e. a negative percent value) indicates an improvement in condition

    Time frame: 12 weeks

  4. Change in GSP

    A reduction from baseline (i.e. a negative percent value) indicates an improvement in condition

    Time frame: 12 weeks

  5. Change in liver fat content as measured by liver fat fraction (FF) with magnetic resonance imaging method.

    A non-invasive method will be utilized to estimate liver fat content (%) by MRI calculated liver FF.

    Time frame: 12 weeks

  6. Change in serum CK-18 fragment levels

    A reduction from baseline (i.e. a negative percent value) indicates an improvement in condition

    Time frame: 12 weeks

  7. Rate of AE/SAE

    Rate of patients who experience AE/SAE at end of treatment

    Time frame: 12 weeks

  8. Rate of AEs leading to discontinuation at end of treatment

    Rate of patients who experience AEs leading to discontinuation at end of treatment

    Time frame: 12 weeks

Other outcomes

  1. Insulin resistance

    Change in insulin resistance at Week 12

    Time frame: 12 weeks

  2. Triglycerides

    Change in serum at Week 12

    Time frame: 12 weeks

  3. Low density lipoprotein

    Change in serum at Week 12

    Time frame: 12 weeks

  4. Total cholesterol

    Change in serum at Week 12

    Time frame: 12 weeks

  5. High density lipoprotein

    Change in serum at Week 12

    Time frame: 12 weeks

  6. Gene expression biomarkers

    Gene expression biomarkers (ACC1, Adfp, AOX, Cat, CCL20, CCR2, Cpt1α, CYP2E1, CYP4A11, CYP7A, Dgat1, Dgat2, FAS, Gapdh, Gpx1, Gpx2, Gpx3, Gpx4, GSS, Hadh, Ho1, HSL, IL-10, IL-1β, IL-6, iNOS, LCAD, NF-κB1, NF-κB2, Pparα, PPARβ/δ, PPARγ, SCD-1, Sod1, Sod2, Sod3, SREBP-1c, TGFβ, TLR4, TNFα, Ucp2, VLCAD, α-SMA, β-actin) related to NASH changes in blood at Week 12

    Time frame: 12 weeks

07

Study locations

1 site
  • Tri-Service General Hospital
    Taipei, 114, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Sep 2021, 49 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2019
First posted
Mar 11, 2019
StartActual
Aug 4, 2017
Primary completionActual
Sep 22, 2021
CompletionActual
Oct 19, 2021
Last update
Jan 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03868566
Lead sponsor
Sinew Pharma Inc.
Responsible party
Sponsor
First posted
Mar 11, 2019
Start date
Aug 4, 2017
Primary completion
Sep 22, 2021
Completion
Oct 19, 2021
Last update
Jan 6, 2023

Study contacts

Yu-Lueng Shih, MD,PhD
principal investigator · Tri-Service General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion